Bookmark
Forward
QuickView for daptomycin (compound)
PubChem Substance
| Name: | Daptomycin |
|---|---|
| PubChem Substance ID: | 12013658 |
| Description: | A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. |
| Synonyms: |
Cubicin; Dapcin; Daptomycin; LY-146032; Cidecin
|
DrugBank
Identification
| Name: | Daptomycin |
|---|---|
| Name (isomeric): | DB00080 |
| Drug Type: | biotech |
| Description: | A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA. |
| Synonyms: |
LY 146032
|
| Brand: | Cubicin |
| Category: | Anti-Bacterial Agents |
| CAS number: | 103060-53-3 |
Pharmacology
| Indication: | For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms. |
|---|---|
| Pharmacology: |
Daptomycin is a 13 member amino acid cyclic lipopeptide antibiotic active against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant Enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci and corynebacteria. Daptomycin is derived ...
show more » |
| Mechanism of Action: |
Daptomycin appears to bind or insert into the outer membrane of gram positive bacteria. The binding and integration of daptomycin into the cell membrane is calcium dependent. Calcium ions cause a conformational change in daptomycin, augmenting its amphipathicity (hydrophilic head group and hydrophobic tail group), leading to incorporation into the ...
show more » |
| Protein binding: | Daptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a concentration-independent manner. The overall mean binding ranged from 90 to 93%. |
| Biotransformation: | Minor amounts of three oxidative metabolites and one unidentified compound have been detected in urine. The site of metabolism has not been identified. |
| Route of elimination: | Daptomycin is excreted primarily by the kidney. In a mass balance study of 5 healthy subjects using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from urine based on total radioactivity (approximately 52% of the dose based on microbiologically active concentrations) and 5.7% of the dose was recovered from feces (collected for up to 9 days) based on total radioactivity. Because renal excretion is the primary route of elimination, dosage adjustment is necessary in patients with severe renal insufficiency (CLCR <30 mL/min) |
| Half Life: | 7 days |
| Affected organisms: | Enteric bacteria and other eubacteria |
Targets
